tradingkey.logo

Nexalin Technology Inc

NXL
查看详细走势图
0.832USD
+0.026+3.29%
收盘 12/19, 16:00美东报价延迟15分钟
15.13M总市值
亏损市盈率 TTM

Nexalin Technology Inc

0.832
+0.026+3.29%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.29%

5天

-9.60%

1月

-15.29%

6月

-20.03%

今年开始到现在

-69.87%

1年

-68.38%

查看详细走势图

TradingKey Nexalin Technology Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Nexalin Technology Inc当前公司基本面数据相对非常健康,增长潜力稳定。当前估值合理,在医疗设备与耗材行业排名122/208位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价4.00。中期看,股价处于下降通道。近一个月,市场表现非常差,但技术面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Nexalin Technology Inc评分

相关信息

行业排名
122 / 208
全市场排名
289 / 4582
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 1 位分析师
买入
评级
4.000
目标均价
+316.41%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Nexalin Technology Inc亮点

亮点风险
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
业绩增长期
公司处于发展阶段,最新年度总收入168.72K美元
利润高增长
公司净利润处于行业前列,最新年度总收入168.72K美元
估值合理
公司最新PE估值-1.29,处于3年历史合理位
机构加仓
最新机构持股1.33M股,环比增加34.88%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值55.70K
活跃度增加
近期活跃度增加,过去20天平均换手率1.05

Nexalin Technology Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Nexalin Technology Inc简介

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
公司代码NXL
公司Nexalin Technology Inc
CEOWhite (Mark)
网址https://nexalin.com

常见问题

Nexalin Technology Inc(NXL)的当前股价是多少?

Nexalin Technology Inc(NXL)的当前股价是 0.832。

Nexalin Technology Inc的股票代码是什么?

Nexalin Technology Inc的股票代码是NXL。

Nexalin Technology Inc股票的52周最高点是多少?

Nexalin Technology Inc股票的52周最高点是3.870。

Nexalin Technology Inc股票的52周最低点是多少?

Nexalin Technology Inc股票的52周最低点是0.702。

Nexalin Technology Inc的市值是多少?

Nexalin Technology Inc的市值是15.13M。

Nexalin Technology Inc的净利润是多少?

Nexalin Technology Inc的净利润为-7.61M。

现在Nexalin Technology Inc(NXL)的股票是买入、持有还是卖出?

根据分析师评级,Nexalin Technology Inc(NXL)的总体评级为买入,目标价格为4.000。

Nexalin Technology Inc(NXL)股票的每股收益(EPS TTM)是多少

Nexalin Technology Inc(NXL)股票的每股收益(EPS TTM)是-0.645。
KeyAI